$CMPI News

Last published 2y ago

2y agoAUPH APLS CMPI TPTX+5Axonis Therapeutics Announces $115 Million Series A FinancingPR NewswireAxonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an...
2y agoAKRO APLS AUPH HRMY+5venBio Raises $528 Million Venture Capital Fund Focused on Life Science CompaniesBusiness Wire- venBio promotes Yvonne Yamanaka, Ph.D. to Partner venBio today announced the closing of venBio Global Strategic Fund V ("venBio Fund V"), its fifth life sciences venture capital fund, exceeding its target and
4y agoCMPI REGN XOMAKuros Biosciences: Completion of the Acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals Triggers a $5 Million Milestone PaymentGlobeNewswireAd-hoc announcement pursuant to Article 53 of the SIX listing rules • $2.5 million of milestone to be paid to XOMA Corporation under royalty agreement SCHLIEREN (ZURICH), Switzerland, June 02, 2022 (GLOBE NEWSWIRE) -- Kuros Biosciences AG ("K
4y agoCMPIUniversity of Iowa Holden Comprehensive Cancer Center Presents Preliminary Data from Clinical Trial of Vidutolimod at the 2022 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewswireCAMBRIDGE, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) ("Checkmate"), a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to co
4y agoCMPICheckmate Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Business UpdateGlobeNewswireCAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) ("Checkmate"), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to com
4y agoACC AXSM CMPI MDVL+1Thinking about buying stock in Axsome Therapeutics, American Campus Communities, Checkmate Pharmaceuticals, Plug Power, or Medavail?PR NewswireNEW YORK, April 19, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AXSM, ACC, CMPI, PLUG, and MDVL.
4y agoCMPI REGNRegeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor TypesPR NewswireProposed ~$250 million all-cash acquisition strengthens Regeneron's portfolio of diverse and combinable immuno-oncology candidates Lead investigational asset vidutolimod is a potential best-in-class TLR9 agonist, with demonstrated clinical responses o
4y agoCMPI REGNRegeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor TypesGlobeNewswireProposed ~$250 million all-cash acquisition strengthens Regeneron's portfolio of diverse and combinable immuno-oncology candidates Lead investigational asset vidutolimod is a potential best-in-class TLR9 agonist, with demonstrated clinical respo
4y agoCMPICheckmate Pharmaceuticals Presents Clinical Trial Biomarker Data with Vidutolimod at the 2022 American Association for Cancer Research (AACR) Annual MeetingGlobeNewswireCAMBRIDGE, Mass., April 08, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) ("Checkmate"), a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to
4y agoCMPICheckmate Pharmaceuticals Announces Full Year 2021 Financial Results and Provides Business UpdateGlobeNewswireAlan Bash, experienced biopharmaceutical executive, appointed President and CEO Clinical trials with vidutolimod (CMP-001) in melanoma, head and neck cancer indications ongoing; Trial dosing initiated in cohorts for PD-1 refractory non-melanoma skin c
4y agoCMPICheckmate Pharmaceuticals to Present at the 2022 American Association for Cancer Research (AACR) Annual MeetingGlobeNewswireCAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) ("Checkmate"), a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to
4y agoCMPICheckmate Pharmaceuticals Appoints Alan Bash as President and CEOGlobeNewswireCAMBRIDGE, Mass., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) ("Checkmate"), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to co
4y agoCMPICheckmate Pharmaceuticals Welcomes Industry Leader Jon Wigginton, M.D. to its Board of DirectorsGlobeNewswireCAMBRIDGE, Mass., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) ("Checkmate"), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to co
4y agoCMPICheckmate Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual ConferenceGlobeNewswireCAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) ("Checkmate"), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to co
4y agoCMPICheckmate Pharmaceuticals Announces Initiation of Patient Dosing in Phase 2 Multi-Indication Trial Using VidutolimodGlobeNewswireCAMBRIDGE, Mass., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) ("Checkmate"), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to co
4y agoCMPICheckmate Pharmaceuticals Strengthens Board of Directors with Appointment of Joy Yan, M.D., Ph.D.GlobeNewswireCAMBRIDGE, Mass., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) ("Checkmate"), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to co
4y agoCMPICheckmate Pharmaceuticals to Present at the Piper Sandler 33rd Annual Virtual Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) ("Checkmate"), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to co
5y agoCMPICheckmate Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Business UpdateGlobeNewswireAlan Fuhrman appointed interim President and CEO Clinical trials with vidutolimod (CMP-001) in melanoma, head and neck cancer indications ongoing Clinical data readouts anticipated in 2022 CAMBRIDGE, Mass., Nov. 12, 2021 (GLOBE NEW
5y agoCMPICheckmate Pharmaceuticals Presents Final Clinical Data for Phase 1b Study Evaluating Vidutolimod at The Society for Immunotherapy of Cancer (SITC) 36th Annual MeetingGlobeNewswireVidutolimod in combination with pembrolizumab demonstrated promising clinical activity in patients with PD-1 blockade-refractory melanoma with an ORR of 23.5% per RECIST v1.1 Vidutolimod also demonstrated monotherapy activity with an ORR of 20.0% pe
5y agoCMPICheckmate Pharmaceuticals to Present at the Jefferies London Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) ("Checkmate"), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to co
5y agoCMPICheckmate Pharmaceuticals Announces Final Data Presentation for Phase 1b Study Evaluating Vidutolimod at The Society for Immunotherapy of Cancer (SITC) 36th Annual MeetingGlobeNewswireCAMBRIDGE, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) ("Checkmate"), a clinical stage biotechnology company focused on developing proprietary technology to harness the power of the immune system to comba
5y agoCMPICheckmate Pharmaceuticals Announces CEO TransitionGlobeNewswireCAMBRIDGE, Mass., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) ("Checkmate"), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to co
5y agoCMPICheckmate Pharmaceuticals Announces Webcast on Innate Immune Modulators and Vidutolimod (CMP-001)GlobeNewswireLive presentation and Q&A moderated by Jefferies Equity Research on Tuesday, October 26, 2021 at 11:00am ET Featured speakers include Jason Luke, M.D., FACP and Art Krieg, M.D. CAMBRIDGE, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Checkmate Pha
5y agoCMPICheckmate Pharmaceuticals to Present at the Cantor Virtual Global Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals Inc. (NASDAQ:CMPI) ("Checkmate"), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to co
5y agoCMPICheckmate Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment ConferenceGlobeNewswireCAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) ("Checkmate"), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to c
5y agoCMPICheckmate Pharmaceuticals Announces Second Quarter 2021 Financial Results and Provides Business UpdateGlobeNewswireClinical trial programs for vidutolimod (CMP-001) in melanoma and head and neck cancer indications ongoing Trial start-up activities to support non-melanoma skin cancer indications underway Multiple clinical data readouts anticipated in 2022 CAM
5y agoCMPICheckmate Pharmaceuticals to Present at the BTIG Virtual Biotechnology ConferenceBusiness WireCheckmate Pharmaceuticals Inc. (NASDAQ:CMPI) ("Checkmate"), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced that Barry Labinger, CEO,
5y agoCMPICMP-001 in Combination With IV PD-1-Blocking Antibody in Subjects With Certain Types of Advanced or Metastatic Cancer - NCT04916002ClinicalTrials.govObjective response rate (ORR) with CMP-001 in combination with a programmed cell death protein 1 (PD-1)-blocking antibody (cemiplimab-rwlc) in study subjects with metastatic or advanced/unresectable CSCC, MCC, or TNBC, Safety and tolerability of CMP-001 administered by intratumoral (IT) injection in combination with a PD-1-blocking antibody (cemiplimab-rwlc) in the study subjects, Efficacy of CMP- ...
5y agoCMPICheckmate Pharmaceuticals to Present at the Jefferies 2021 Virtual Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., May 20, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals Inc. (NASDAQ:CMPI) ("Checkmate"), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to comb
5y agoCMPICheckmate Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Update on Recent ProgressGlobeNewswireCAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) ("Checkmate"), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to com
5y agoCMPICheckmate Pharmaceuticals Announces Clinical Supply Agreement with Regeneron to Evaluate Vidutolimod (CMP-001) in Combination with Libtayo® (cemiplimab)GlobeNewswireCAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) ("Checkmate"), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to com
5y agoCMPICheckmate Pharmaceuticals Announces Initiation of Patient Dosing in Potential Registration Trial of Vidutolimod (CMP-001) in Patients with Anti-PD-1 Refractory Advanced MelanomaGlobeNewswireCAMBRIDGE, Mass., May 04, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) ("Checkmate"), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to com
5y agoCMPICheckmate Pharmaceuticals to Present at the Bank of America Securities 2021 Virtual Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals Inc. (NASDAQ:CMPI) ("Checkmate"), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to co
5y agoCMPICheckmate Pharmaceuticals Announces Initiation of Patient Dosing in Phase 2 Head and Neck Cancer TrialGlobeNewswireCAMBRIDGE, Mass., April 19, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals Inc. (NASDAQ:CMPI) ("Checkmate"), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to co
5y agoCMPICheckmate Pharmaceuticals Presents New Clinical Trial Translational Data with Vidutolimod at the 2021 American Association for Cancer (AACR) Annual MeetingGlobeNewswireCAMBRIDGE, Mass., April 11, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary...
5y agoCMPICheckmate Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Update on Recent ProgressGlobeNewswireCAMBRIDGE, Mass., March 29, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary...
5y agoCMPICheckmate Pharmaceuticals to Present Data at the 2021 American Association for Cancer Research (AACR) Annual MeetingGlobeNewswireCAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary...
5y agoCMPICMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma - NCT04698187ClinicalTrials.govDetermine confirmed objective response (ORR) with CMP-001 in combination with nivolumab in subjects with refractory unresectable or metastatic melanoma, Evaluate the safety and tolerability of CMP-001 administered by IT injection in combination with nivolumab, Duration of response (DOR), (and 11 more...)
5y agoCMPICheckmate Pharmaceuticals Announces Key Additions to Executive Management TeamGlobeNewswireRobert F. Dolski appointed as Chief Financial Officer Katherine Eade appointed as General Counsel CAMBRIDGE, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI)...
5y agoCMPICheckmate Pharmaceuticals Announces Clinical Collaboration with Bristol Myers Squibb to Evaluate CMP-001 in Combination with NivolumabGlobeNewswireCAMBRIDGE, Mass., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate Pharmaceuticals”), a clinical stage biopharmaceutical company focused on developing its...
5y agoCMPICheckmate Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides an Update on Recent ProgressGlobeNewswireCAMBRIDGE, Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biotechnology company focused on developing its proprietary...
6y agoCMPICheckmate Pharmaceuticals Presents Updated Clinical Data with CMP-001 at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual MeetingGlobeNewswireCMP-001 in combination with pembrolizumab continues to demonstrate durable responses in anti-PD-1 refractory melanoma in ongoing trial Encouraging new data on pathological responses and 1-year RFS...
6y agoCMPICheckmate Pharmaceuticals to Present at the Upcoming Jefferies Virtual London Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biotechnology company focused on developing proprietary technology...
6y agoCMPICheckmate Pharmaceuticals Announces Data Presentations for CMP-001 at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual MeetingGlobeNewswireCMP-001 in combination with pembrolizumab continues to demonstrate durable responses in anti-PD-1 refractory melanoma Encouraging new data on pathological responses and 1-year RFS with neoadjuvant...
6y agoAIMT MTEM INZY PSTX+4Longitude Capital Raises $585 Million Fund to Invest in Transformative Healthcare CompaniesGlobeNewswire- Longitude Venture Partners IV will build on the Firm’s commitment to improve clinical outcomes, enhance patient quality of life, and drive efficiency in healthcare delivery - - In 2020 to date,...
6y agoCMPICheckmate Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides an Update on Recent ProgressGlobeNewswireSuccessfully completed IPO in August 2020 raising $76.6 million in gross proceedsOn track to initiate planned new clinical trials in melanoma and head and neck cancer CAMBRIDGE, Mass., Sept. 18,...
6y agoCMPINew patent application published for: Combination Tumor ImmunotherapyUS Patent Applications (USPTO)
6y agoCMPIKuros Biosciences’s licensee Checkmate Pharmaceuticals completes its IPO on NASDAQGlobeNewswireTotal gross proceeds raised by Checkmate in IPO of $86.25 million (including sale of overallotment shares)Intention to use part of the net proceeds from the IPO to fund the development of its product...
6y agoCMPICheckmate Pharmaceuticals Announces Pricing of Initial Public OfferingGlobeNewswireCAMBRIDGE, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI), a clinical stage biotechnology company focused on developing proprietary technology to harness the...